Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Total Current Liabilities (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Total Current Liabilities for 6 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 12.28% year-over-year to $30.6 million, compared with a TTM value of $30.6 million through Dec 2025, down 12.28%, and an annual FY2025 reading of $30.6 million, down 12.28% over the prior year.
  • Total Current Liabilities was $30.6 million for Q4 2025 at Treace Medical Concepts, down from $40.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $47.0 million in Q1 2024 and bottomed at $8.6 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $28.8 million, with a median of $30.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities skyrocketed 110.58% in 2022, then decreased 29.48% in 2025.
  • Year by year, Total Current Liabilities stood at $18.2 million in 2021, then surged by 66.09% to $30.2 million in 2022, then skyrocketed by 48.89% to $45.0 million in 2023, then dropped by 22.45% to $34.9 million in 2024, then decreased by 12.28% to $30.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for TMCI at $30.6 million in Q4 2025, $40.9 million in Q3 2025, and $41.9 million in Q2 2025.